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Abstract 
Diagnostic tests are an essential component of clinical medicine today. 
Like any other clinical study, the results of studies evaluating new diagnostic tests 
must be interpreted in the context of underlying methodological problems and 
generalizability. Subgroup variation in diagnostic test accuracy, the focus of this 
paper, can arise in two ways: the test truly performs differently in the two 
subgroups or it is an artifact. Real subgroup variation affects the generalizability 
of the results. Artifacts, however, arise from biased measurement (e.g. an 
imperfect reference standard) and affect the believability of the results. The 
question is whether real subgroup variation can be separated from artifact. 
Sources of subgroup variation and examples are presented with the 
specific focus on true subgroup variation and spurious variation due to the use of . 
imperfect reference standards. Both true variation and the use of imperfect 
reference standards are shown to be quite common. Frequently used tests, such as 
the urine dipstick for urinary tract infection, exhibit true subgroup variation. 
Observed test characteristics derived from comparison to an imperfect reference 
are shown to be prevalence-dependent. The effect of measurement reliability is 
discussed as a third source of potential subgroup variation. 
Two basic approaches for managing imperfect reference standards are 
reviewed: estimation techniques and methods for augmenting imperfect 
references. The emphasis is on the method ofHui and Walter, which provides a 
closed form expression for identifYing the unknown characteristics of the new test 
and the reference test in two populations. An alternate derivation is also provided 
that may be more accessible to the non-statistician. 
Methods for identifying true subgroup variation, simple stratification and 
regression analysis, as well as methods for incorporating subgroup variation into 
clinical decision making are presented to round out the general discussion of 
subgroup variation. IdentifYing subgroup variation and accounting for covariates 
in diagnostic test parameters is not significantly different from similar analyses in 
studies of interventions. The use of likelihood ratios to measure the impact of 
subgroup variation on decision making as well as a means for mitigating poor 
generalizability ("spectrum bias") of a test when used in a population with a 
different severity of disease completes the discussion. 
The paper is concluded with a methodology for distinguishing true 
subgroup variation from spurious subgroup variation due to an imperfect 
reference standard. 
I Introduction 
Diagnostic tests are an essential component of clinical medicine today. 
Like any other clinical study, the results of studies evaluating new diagnostic tests 
must be interpreted in the context of underlying methodological problems and 
generalizability. Subgroup variation in diagnostic test accuracy can arise in two 
ways: the test truly performs differently in the two subgroups or it is an artifact. 
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Real subgroup variation affects the generalizability of the results. Artifacts, 
however, arise from biased measurement (e.g. an imperfect reference standard)1 
and affect the believability of the results. The question is whether real subgroup 
variation can be separated from artifact. 
Imperfect reference standards are a common problem2 Pathologists are 
not 100% accurate and they may have reporting preferences dictated by where 
they trained. Bacterial culture, a frequently used reference, is not 100% sensitive. 
Pulmonary angiography for pulmonary embolism is not 100% sensitive. Under 
idealized circumstances, the use of an imperfect reference results in 
underestimation of one or both of a test's sensitivity, the proportion of diseased 
cases that test positive, and specificity, the proportion of non-diseased cases that 
test negative. First noted by Gart and Buck in 1966/ the effect on the observed 
test characteristics is dependent on disease prevalence. See Figures 1 and 2. If 
the performance characteristics of the imperfect reference are known, then the 
new test's characteristics can be corrected algebraically. 4 
When a test performs differently in two subgroups leading to different test 
characteristics in the two groups, the test is said to exhibit "spectrum effect" or 
"spectrum bias. "5 Diagnostic testing studies usually report the results for the 
entire study sample leading to a weighted average of the sensitivities and 
specificities for each of the subgroups. This is inappropriate as the weighted 
average no longer applies to either group. In some cases, clear biological 
differences can explain differential test performance. Tests relying on antibody 
detection are likely to perform less well in immunocompromised patients 
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(decreased sensitivity). Similar tests performed in patients with autoimmune 
diseases experience greater risk for antibody cross-reactivity, which leads to 
decreased specificity. 
An imperfect gold standard can mimic spectrum effect when the 
prevalence of the disease or condition of interest is different in the subgroups. 1 
Inappropriate assigmnent of true case/noncase can greatly affect the computed 
performance characteristics of the test under study. This situation may arise when 
studying symptomatic versus asymptomatic people. The prevalence of disease is 
likely much greater among symptomatic individuals than in asymptomatic 
individuals. 
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Figure 1: Observed specificity as a function of prevalence for several values of 
reference test sensitivity. The test's true specificity in this example is 0.80. As 
sensitivity of the reference decreases, the observed specificity decreases as 
prevalence increases. 
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Figure 2: Observed sensitivity as a function of prevalence for several values of 
reference test specificity. The test's true sensitivity in this example is 0.80. As 
specificity of the reference decreases, the observed sensitivity decreases as 
prevalence decreases. 
There are three goals for this paper. The first is to review potential 
sources of observed subgroup heterogeneity. An emphasis will be placed on true 
subgroup variation and on imperfect reference standards. The second is to 
provide an overview of current methods used for addressing the problems 
introduced by an imperfect reference and for identifYing subgroup heterogeneity. 
The emphasis will be on simple methods making use of information across 
subgroups to estimate the properties of the reference test. The impact of subgroup 
variation in clinical decision making will also be explored. The final goal is to 
present a methodology for distinguishing true subgroup variation from spurious 
variation introduced by an imperfect reference. 
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II Background 
ll.l Subgroup Variation 
ll.l.l "Spectrum" 
The use of the term "spectrum" in relation to biases and population 
subgroups when discussing diagnostic tests is confusing. On the one hand, when 
used in the phrase "adequate spectrum," it refers to the range of subjects against 
which a test should be evaluated to arrive at a single set of test characteristics. On 
the other hand, when used in the phrase "spectrum bias" or "spectrum effect," it 
implies different test characteristics across subgroups. Subgroup variation among 
tests has been recognized at least since the 1970s, yet the systematic exploration 
of subgroup variation is still not a component of typical diagnostic test evaluation 
studies. An unintended consequence of using the phrase "adequate spectrum," 
which is still a component of all guidelines for diagnostic test evaluations, may be 
that subgroup analysis of diagnostic tests is not pursued to the extent they should 
be. The following discussion tracks the evolution of the concept of spectrum 
from its initial introduction to its current day usage. 
Ransohoff and Feinstein first introduced the concept of"spectrum" in 
19786 In their usage of the term, diagnostic tests need to be evaluated on a 
sufficiently broad "range of features found in patients" to get a more accurate 
depiction of the sensitivity and specificity of a test. This broad range should 
include a broad range of pathologies, a broad range of symptomatic severity, and 
a broad range of individuals with comorbid conditions. The consequences of 
using an inappropriate spectrum during the development or study of a test are that 
the test performs poorly in practice. 
Subsequently, in 1988, Miller, et al} subdivided Ransohoff and 
Feinstein's "spectrum" into selection bias and "disease-based spectrum." In 
selection bias, there is a spurious association between a patient characteristic and 
the diagnosis of interest. In "disease-based spectrum" bias, a restricted range of 
patients is recruited into a study based on an intermediate to high probability of 
disease. In other words, selection is based on a restricted range of disease 
severity. An example of such bias is the selection of patients for angiography. 
These patients have already received several tests indicating a significant 
likelihood for coronary artery disease (CAD). Generalization of test 
characteristics derived from populations exhibiting these biases will be poor. 
In 1990, the term "spectrum bias" was first used by Nardone, et al} to 
refer to the use of an inappropriate spectrum of patients in past studies of the 
diagnosis of anemia by skin pallor. In this case, an inappropriate spectrum 
appears to have been any study that did not have equal numbers of anemic and 
normal patients. Although this is not exactly what Ransohoff and Feinstein meant 
by appropriate spectrum, they did go to great lengths to design a study with equal 
proportions of patients in 5 different hematocrit ranges. They find that the 
sensitivity of skin pallor was greater the lower the hematocrit, which corroborates 
many subsequent findings that test sensitivity is greater the more severe the 
disease is. 
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In 1992, Lachs, et al., 9 first associate the term "spectrum bias" with 
different test characteristics in a pair of subgroups. In this study of diagnosis of 
urinary tract infection by urine dipstick, the aggregate sensitivity and specificity 
was found to be 83% and 71%, respectively. When divided into groups based on 
high versus low pretest probability, the sensitivity and specificity was found to be 
92% and 42%, respectively, in the high probability group and 56% and 78%, 
respectively, in the low probability group. This paper is the firstto note caution 
when aggregating test characteristics among subgroups. Unfortunately, they also 
state that "spectrum bias will not produce misleading appraisal of test 
performance if the groups recruited for the study are representative of the patients 
in whom it will ultimately be used in clinical practice." This is incorrect because 
there may be subgroup variation within the typical range of clinical practice 
patients. An example of subgroup variation that is cited in their article that is 
counter to their statement is the use of exercise stress testing for coronary 
ischemia in men and women. Sensitivity of exercise stress testing for coronary 
ischemia in men is 72.4% and in women it is 57.2%; 10 and, for the presence of 
coronary artery disease, the sensitivity is 63.5% in men and only 29% in 
women. 11 
Finally, in 2002, Mulherin and Miller5 refer to the variation of test 
characteristics among subgroups as "spectrum effect." They argue that this is not 
a systematic bias that needs to be controlled against. Rather, this is an example of 
effect modification- the diagnostic test simply performs differently in different 
subgroups. Reporting aggregate test characteristics is, therefore, inappropriate. 
Characteristics for each subgroup in which variation is found should be reported 
separately. 
The concept of appropriate spectrum in diagnostic tests as described by 
Ransohoffand Feinstein's definition of spectrum as "the range of features found 
in patients used to challenge a test's sensitivity and specificity"6 (p. 927) to be 
reported as a single set of characteristics is now supplanted by the need for the 
consideration of variation in test characteristics among subgroups. Although 
subgroup differences have been recognized in the diagnostic testing literature for 
specific tests (see Table 1), the formal discussion of the spectrum effect provides 
a framework to explore subgroup variation in all diagnostic tests. The 
consequence of this, however, is that greater effort must be made at adequate 
representation of subgroups of interest in evaluation studies. 
A further point regarding spectrum needs to be made. There are two 
components to the evaluation of a diagnostic test prior to its introduction to 
general use6 First, in evaluating the sensitivity of the test it is important to 
provide adequate examples of disease across its many manifestations and in the 
presence of co morbid conditions. Second, as many mimics of the condition of 
interest as possible need to be presented to the test to properly evaluate the test's 
specificity. It is inappropriate to only evaluate the specificity in a population of 
normal individuals. (A possible exception to this is when the test is used for 
screening purposes.) The concept of a broad range of evaluation conditions is the 
original concept of spectrum as defined by Ransohoff and Feinstein. However, 
that the test may behave differently when exposed to certain parts of the broad 
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range of manifestations or comorbid conditions and that this behavior should be 
explicitly reported has only recently been formally recognized. 
Ultimately, designing and evaluating studies of diagnostic tests should be 
no different from designing intervention studies. In the classic 1987 paper by 
Colin Begg, 12 he states that "it may seem anachronistic to caution statisticians to 
consider adjustment for covariates ... given that covariate adjustment has been a 
major topic of study in statistics for much of this century. However, in the 
majority of test efficacy studies the issue is not addressed."(p 413l Consideration of 
covariates, i.e. subgroups, is increasing, albeit slowly. Like intervention studies, 
consideration of selection bias, subgroup analysis, and generalizability should be 
fundamental aspects of study design and critical appraisal. 
11.1.2 Examples 
Table !lists all studies of diagnostic tests identified by searches on 
"spectrum bias" and "spectrum effect" on PubMed. (There is no MeSH term for 
this concept.) Included in this table are examples of other diagnostic testing 
modalities reporting subgroup variation. A key point from examination of this 
table is the presence of significant subgroup variation in frequently used tests. 
Urine dipsticks and the rapid antigen test for "strep throat" are frequently used 
tests in emergency departments and primary care offices. Electrocardiograms are 
also frequently obtained. With the high prevalence of obesity today, 
understanding that body mass index (BMI) does not perform well for people less 
than 80 kilograms (172 pounds) is important. For completeness, one study13 and 
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one editorial14 that specifically mention "spectrum bias," but got the definition 
incorrect, are included in the list. 
Table 1: Subgroup Variation in Diagnostic Tests 
Study/ "Spectrum Diagnosis Of Notes 
Report Bias"" 
Characteristic Sens Spec 
Hlatky,'" N Coronary ischemia Typical angina 79.6 80.9 
1984 via exercise EKG Atypical angina 52.8 82.7 
Men 72.4 83.1 
Women 57.2 85.9 
Age < 40 years 56.2 83.7 
Age > 60 years 84.4 70.0 
Fletcher," N Colon cancer Duke A orB 36 87 
1986 screening via Duke CorD 74 83 
carcinoembryonic 
antigen 
Detrano,16 N Coronary ischemia PreviousMI 95.6 NR 
1988 via exercise No previous MI 79.1 NR 
thallium 
scintigraphy 
Levy,'' 1990 N Left ventricular Obese, highest quartile 
hypertrophy via Nonobese, lowest quartile 5.7 98.9 
EKG 
14.2 98.3 
Lachs,' 1992 y Urinary tract High probability 92 42 
infection via urine Low probability 56 78 
dipstick 
O'Connor," y Multiple sclerosis High probability 70 93 
1996 viaMRI Low probability 20 80 
Kallmes," y Carotid artery General population NR 87 
1996 stenosis via MRA Confirmatory test after 
positive duplex 
sonography 62 
Moons," N Coronary artery Typical angina 61.2 97.2 
1997 disease via exercise Atypical angina 50.9 94.1 
stress test Men 63.5 88.5 
Women 29.7 97.2 
Curtin,'" 1997 y Obesity via body <60kg 0 100 
mass index <: 60 to 70 kg 14.3 100 
<: 70 to 80 kg 17.7 100 
<: 80 kg 54.6 100 
Dagnelie," N Group A beta- High probability 75 NR 
1998 hemolytic Intermediate or low 
streptococcal probability 48 NR 
pharyngitis in 
adults via rapid 
antigen test 
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Study/ 
Report 
Barnhart, 14 
1999 
Colin, 22 2000 
DiMatteo," 
2001 
Mulherin/ 
2002 
Huot," 2002 
,, Lim, 2003 
Hall," 2004 
"Spectrum Diagnosis Of 
Bias"'" 
Y Infertility via FSH 
Y Hepatitis C via 
'b d I anti o y sera ogtes 
(RIBA 3'• 
generation) 
y Group A beta-
hemolytic 
streptococcal 
pharyngitis in 
adults via rapid 
antigen test 
y Chlamydia 
· trachomatis 
infection via 
enzyme 
immunoassay 
y Renal artery 
stenosis via 
captopril renal scan 
.. Y Cogmllve 
impairment via two 
questionnaires 
Y Group A beta-
hemolytic 
streptococcal 
pharyngitis in 
children via rapid 
antigen test 
NR - not reported. 
'study explicitly mentions "spectrum bias." 
Notes 
Characteristic I Sens I Spec 
Paper and editorials describe use of test 
with the same performance in populations 
with different prevalence of disease (older 
and already failed IVF versus younger 
patients) 
Qualitative consideration of antibody tests 
. d. d' 'd I m tmmunocompromtse m tvt ua s 
Chronic liver disease 100 100 
Hemodialysis 
79 100 
Modified Centor criteria: 
0,1 
2 61 NR 
3 76 
4 90 
97 
Age<24 75.9 99.5 
Age;e24 58.3 99.2 
With vascular disease 
Without vascular disease 70 63 
100 55 
Different performance between two 
screening instruments on same group 
erroneously attributed to spectrum bias 
Modified Centor criteria: 
0 
I 47 NR 
2 65 
3,4 82 
90 
Two further areas of intense clinical interest where subgroup variation is 
present are in the early detection of breast cancer via screening mammography 
and in the diagnosis of pulmonary embolism (PE) via pulmonary angiography 
and, possibly, the D-dimer assay. There has been a significant amount of 
literature devoted to screening mammography and variations in accuracy by 
subject characteristics. 26.27.28'29'30•31 For example, sensitivity of screening 
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mammography is lower among younger women than in older women. In 
pulmonary angiography, whether by computed tomography ( CT) or magnetic 
resonance (MR), there is a clear difference in the ability of these techniques to 
detect large vessel emboli and subsegmental emboli. 32•33.34.35 
Table 2: Examples of Subgroup Variation in the Performance of Screening 
Mammography 
Characteristic Sensitivity Specificity 
Age26 
40-44 68.6 90.9 
50-54 75.4 91.6 
60-69 72.8 93 
80-89 83.3 94.3 
Breast densi 
Extremely dense 62.2 89.9 
Almost entirely fatty 88.2 96.5 
High Risk (Family history or 29 98 
BRCAI/2 29 
Obesity 
BMI<25 Referent Referent 
BMI>35 OR l.l3 OR0.77 
Hormone Replacement Therapy" 
Current User 
Never Used 83.0 96.4 
92.1 97.9 
Invasiveness 
In situ 37 NR 
Invasive 72 
Considerable attention has been given to subgroup variation in the 
screening mammography literature. Table 2 provides examples of published 
variations in test characteristics among subgroups and is not meant to be an 
exhaustive synthesis of the available data on each of the listed subgroups. 
Conflicting data do exist, especially regarding the effect of hormone replacement 
therapy,26•31 so the data serves for illustration only. As is common in studies of 
interventions, some identified subgroups may in fact be proxies for other 
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b 
1 
' h 
underlying characteristics. For example, age is most likely a proxy for breast 
density. What is important is that subgroup variation is being explored, because 
clinically important subgroups exist. In particular, mammography does not 
perform well at all in women who are at high risk of breast cancer compared to 
the woman at average risk. 
The diagnosis ofPE is also subject to subgroup variation. In this case, 
subsegmental emboli seem to represent a different entity. Many may actually 
represent incidental findings and, if truly associated with the event, do not carry 
the same clinical significance that an embolism found in a larger pulmonary 
vessel would have in the near term. 36•37 Regardless of this fact, angiographic 
methods have difficulty with detecting emboli in the smaller vessels. The reason 
for this difficulty is due to a combination of motion artifact and poor spatial 
resolution.· Since fluoroscopic pulmonary angiography is the de facto gold 
standard, one can only discuss inter-rater variability when discussing its accuracy. 
Stein, et al.,32 using the degree of co-positivity between two observers, found that 
co-positivity for presence of an embolus in a subsegmental artery was 66% 
compared to a co-positivity of 90% and 98% in the segmental and central or lobar 
arteries, respectively. For single-slice CT, Goodman, et al.,32 found a sensitivity 
of 86% in the central arteries and only 25% in the subsegmental arteries for the 
diagnosis ofPE. Modern multislice CT scanners perform significantly better and 
are able to visualize the subsegmental arteries twice as well as single-slice 
scanners. 34 Magnetic resonance angiography (MRA), which also has difficulty 
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with the smaller vessels, has reported sensitivities of 40% for subsegmental, 84% 
for segmental and 100% for central or lobar PE. 35 
According to the study by De Monye, et al.,38 the D-dimer test for PE also 
displays subgroup variation by location. The test had a sensitivity of93% for PE 
located in the segmental or larger arteries and a sensitivity of only 50% when the 
embolism was located in the subsegmental arteries. The D-dimer assay has good 
performance for ruling out large vessel PE, but relatively poor performance for 
ruling out smaller emboli. Since this assay is usually only obtained in a patient 
with a low clinical suspicion ofPE and an individual with a large vessel PE is 
unlikely to be asymptomatic, then a negative test would be falsely reassuring. 
Subgroup variation in diagnostic test performance clearly exists for the 
tests used for many common problems. The reporting of aggregate test 
characteristics across all patients distorts the performance· of the tests in clinically 
important subgroups. Hopefully, understanding this variation will lead to more 
appropriate use of diagnostic tests, which will ultimately lead to better care for 
patients. 
ll.1.3 Does This Test Exhibit Subgroup Variation? 
When considering the possibility that a subgroup may behave differently 
from the larger group that a test is normally used in, there are some clues to 
consider. These include biological plausibility and wide variations in published 
test characteristics. By understanding the scientific basis for a given test, 
scenarios can be conceived where the mechanism can be thwarted leading to an 
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erroneous test result. By examining the published literature for a given test, wide 
variations in published test characteristics are clues to heterogeneity39 The 
heterogeneity may be due to poor study design or it may be due to selection of 
different sets or proportions of subjects. 
Predicting subgroup variation on the basis oftest mechanism is not 
difficult. Tests relying on the detection of antibodies do not perform as well in 
people who are deficient in antibodies. Imaging fine anatomical structures, such 
as small pulmonary arteries, will be difficult if the patient moves or if the spatial 
resolution of the technique is not adequate. Visualizing abnormalities in dense 
breast tissue is more difficult than in fatty breast tissue. On the other hand, 
finding subgroup variation may lead one to rethink the disease and/or testing 
process. Why does exercise stress testing not perform well in women compared 
to men? Why does the rapid antigen test for Group A beta-hemolytic 
streptococcal pharyngitis perform better the more severe the disease is? 
Heterogeneity between studies of diagnostic tests can be due to a number 
offactors: study design and conduct; population (and circumstances) under study; 
and choice of reference test. 39 Many biases can be introduced in the conduct of a 
diagnostic testing study. Unfortunately, proper design and conduct of diagnostic 
testing trials has not received the attention that intervention trials have received. 
Today, however, guidelines for the proper design and reporting of these studies 
are available40·41 The choice of reference test can lead to different results. For 
example, now that fluoroscopic pulmonary angiography is known not to be 100% 
accurate, a composite reference standard to evaluate a D-dimer assay may include 
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CT angiography plus lower extremity venous Doppler ultrasound to improve the 
reference standard's sensitivity for diagnosing PE. In many cases, there is likely 
to be selection bias in the evaluation of a test, where a particular subgroup is over 
(or under) represented. If all other factors are equal, this is a strong clue that there 
may be subgroup variation. 
Systematic reviews of diagnostic tests are confronted with a particular 
difficulty. Diagnostic test performance is reported as two quantities. The usual 
tests for heterogeneity rely on the presence of only one quantity of interest. In a 
review of the use of tests for heterogeneity in systematic reviews of diagnostic 
tests, Dinnes, et a!., note that "the under use of statistical tests and graphical 
approaches to identify heterogeneity perhaps reflect the uncertainty in the most 
appropriate methods to use ... " 39 (p. iii)_ There is clearly more work that needs to 
be done in this area. 
As a final caveat, diagnostic tests based on dichotomizing continuous 
outcomes may appear to have different test characteristics simply by using a 
different threshold. 12•39 The receiver operating characteristic (ROC) curve should 
be examined in these cases as it provides a description of the separability of the 
two classes, diseased and not diseased. If the curve is identical, the tests are the 
same despite the use of different thresholds. 
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ll.2 Imperfect Reference Standard 
ll.2.1 Examples 
Imperfect reference standards are common in many aspects of diagnostic 
testing. Microbiological testing is an area that has struggled with imperfect 
references for many years. Culture is never 100% sensitive. In a comparison of 
diagnostic methods for chlamydia] urogenital infection by Biro, et aL,42 culture 
sensitivity was in the range of 75% to 80%. Even PCR for detection of viral (or 
other organism) RNA is not 100% perfect. The gold standard against which PCR 
for hepatitis C virus was evaluated was through inoculation of chimpanzees. 22 
Microscopy for the detection of malaria on thick blood smears is considered to be 
the gold standard for diagnosing malaria in field trials. Unfortunately, when 
compared with expert review, microscopy has a sensitivity of91% and a 
specificity of 71%. 43 
Angiography is another area where imperfect reference standards exist. 
Fluoroscopic pulmonary angiography, as noted before, is not perfect at imaging 
the smaller pulmonary arteries. Angiography of the renal arteries also does not 
have perfect sensitivity. In a study evaluating the accuracy of CT angiography 
and MR angiography for the diagnosis of renal artery stenosis, three separate 
observers evaluated the fluoroscopically obtained images to arrive at a consensus 
diagnosis. 44 
Finally, pathological examination of specimens is not 100% sensitive. 
Sampling error is an obvious source of false negatives. A less obvious source of 
error, however, is due to lack of consensus among pathologists on pathological 
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definitions. While most pathologists can agree on the extremes of disease, 
borderline cases cause a great deal of difficulty. Interobserver variability can be 
quite high in some circumstances. For an interesting discussion with examples, 
see the 2003 editorial by LiVolsi45 and the response by Ackerman46 Some 
examples: from LiVolsi, agreement as to the benign or malignant nature of a 
papillary lesion with a follicular pattern in thyroid tissue is around 50%; and, from 
Ackerman, discordance among experts on the diagnosis of a melanocytic 
neoplasm ranges from 26% to 80% depending on the panel. 
The imperfect gold standard is a common problem in the evaluation of 
diagnostic tests. The general effect of using an imperfect reference, especially 
when the new test and the reference test are conditionally independent, is to cause 
underestimation of the new test's performance. As noted previously, this 
underestimation is dependent on the prevalence of disease and may, additionally, 
produce spurious subgroup variation when subgroups have different prevalences 
of disease. 
II.2.2 . Is This Reference Test Imperfect? 
When evaluating a test as a possible reference or when appraising an 
article on a diagnostic test, there are some clues that may be useful in evaluating 
the quality of the reference. Since there is no comparison for a "gold standard" 
test, two features of a test may indicate less than perfect performance in practice. 
First, if there is interobserver variation in the interpretation of the test, especially 
if not low or it is variable between study sites, then the reference test is not likely 
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to be perfect Second, if adjudication of the test requires differentiation of 
borderline cases or requires grading on a continuum divided by a threshold, then 
the test is unlikely to be perfect Many radiological and pathological tests suffer 
both from interobserver variability and dichotomization of continua. Any test 
making use of a human observer should be subject to considerable scrutiny. A 
third category is the use of composite reference standards. Composite references 
are composed of imperfect reference tests, which rarely make a perfect reference 
in the aggregate. 
ll.3 Measurement Error 
The role of measurement error on subgroup heterogeneity will be 
mentioned here. For tests based on dichotomization of a continuous measure, 
measurement error causes degradation of test performance47'48 Confusion exists, 
however, regarding the dependence of this performance degradation on 
prevalence. In 1997, Brenner and Gefeller published a provocative paper that 
suggested significant variation of sensitivity, specificity, positive predictive value, 
and negative predictive value in the presence of noise with disease prevalence. 48 
In a letter to the editor, Bender, et al., 49 took issue with their stance, arguing that 
the model system in which Brenner and Gefeller arrived at their results was 
outside the paradigm of what is normally considered to be "diagnostic testing" 
and would be misleading to the clinicians making use of these tests. For the 
traditional diagnostic testing paradigm, where test characteristics are evaluated 
based on comparison to a gold standard, the effect of noise on test performance 
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should not be related to prevalence. To paraphrase Brenner and Gefeller, they 
would rebut by saying that many more diagnostic decisions are made based on 
subdividing a single distribution of some characteristic in the population into 
"diseased" versus "not diseased" .and that noise can have profound effects on test 
performance as a function of prevalence. Furthermore, they argue that diagnostic 
decision theory, as a field, needs to come to terms with this effect. As it turns out, 
both points-of-view are correct. What follows is an illustration of how 
measurement noise affects test characteristics under the two paradigms. 
ll.3.1 Measurement Reliability 
To provide a framework for discussing measurement noise, the concept of 
measurement reliability is discussed here. An inherent amount of variation is 
present in any measurement. This variation may be intrinsic to the process being 
measured or it may reflect variation in the population and is typically accounted 
for in descriptions of how this continuous measure varies in the population. 
Unwanted variation, however, whether due to environmental conditions (e.g., heat 
exposure during transport), observer variation, or other factors, can degrade the 
reliability of one's measurement. Statistically, measurement reliability, p, is 
conceptualized as the proportion of the variance due to the intrinsic processes, cri2, 
over the total variance, cr? + cr/, where cr/ represents the variance introduced by 
measurement error: p = cr?/(cr? + o-/)47 High reliability coefficients indicate that 
unwanted variance contributes little to the overall variance in observed 
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measurements. Low reliability coefficients indicated that unwanted variance 
contributes significantly to the overall variance of observed measurements. 
Measurement error does not only arise from unwanted environmental 
intrusions, inherent limitations of laboratory equipment, or variations among 
observers. Application of a measurement system with a particular underlying 
assumption about the distributions of interest to a population with a different set 
of distributions can also result in a significant degradation of the reliability of 
one's measurements. When spectrum bias is viewed in terms of measurement 
reliability, application of a test in a population in which the test was not evaluated 
can result in a significant reduction in the reliability of the result. 
The simulations presented in the next two sections make use of 
measurement reliability to illustrate the effects of measurement error on test 
performance. As a point of reference, a good reliability for laboratory tests is 
0.947 
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ll.3.2 Two-Distribution Paradigm 
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Figure 3: Two-distribution paradigm. Distributions of a continuous test result 
for both diseased and non-diseased individuals are shown (solid lines). The 
addition of noise causes a broadening of the distributions (dotted lines). The 
·increased overlap leads to increased false negatives (more area under the curve to 
the left of the threshold for the diseased + noise distribution when compared to the 
diseased without noise distribution) and increased false positives (more area under 
the curve to the right of the threshold for the non-diseased + noise distribution 
when compared to the non-diseased without noise distribution). 
In classic diagnostic testing, test characteristics are derived by comparing 
the results of a test to a gold standard. In this case, the distributions of values for 
a particular measure are known and separate for both diseased and healthy 
individuals. Since two distributions are involved, I have termed this the "two-
distribution paradigm." 
Selection of a decision threshold, and its position relative to the two 
distributions, determines the sensitivity and specificity of the test. The addition of 
noise affects each distribution separately. Noise typically adds variance to any 
measurements with the result that the observed distributions are broader. Since 
evaluations of sensitivity only relate to samples drawn from the distribution of 
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diseased individuals and the location of a threshold, sensitivity is only affected by 
alterations of the distribution. The relative number of samples of a population 
from the diseased distribution does not affect this process. Thus, sensitivity is not 
dependent on prevalence. The same is true for specificity. 
Figure 3 illustrates distribution functions for diseased and non-diseased 
individuals and then, superimposed, the same distributions with noise added in. 
By examining the graphs, one can see that the number of false positives and false 
negatives are increased in the presence of noise. The probability of this occurring 
is only dependent on whether the subject is diseased or non-diseased. The actual 
number in a sample does not affect this probability. Therefore, noise degrades 
performance in this paradigm, but it is not dependent on the prevalence of disease. 
Figure 4 shows the ROC curve for varying levels of measurement reliability. 
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Figure 4: ROC curve and test characteristics for varying levels of reliability. The 
ROC curve shows the test without the influence of noise (solid line) and several 
ROC curves resulting after the introduction of noise (dotted lines). The arrow 
shows the direction of increasing noise (and decreasing reliability). The plot of 
test characteristics follows the sensitivity and specificity, which are equal in this 
case (point with * on ROC curve), with declining reliability. 
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Figures 5 and 6 show the results of simulations designed to evaluate the 
effect of prevalence on test characteristics at varying levels of measurement 
reliability. The distributions are both normal with variance 4. The mean of the 
non-diseased distribution is 6 and the mean of the diseased distribution is I 2. The 
simulation was run for six values of p, ranging from 0.1 to 1.0, and 19 values of 
prevalence, ranging from 0.05 to 0.95 at 0.05 increments. Two hundred thousand 
subjects contributed to the estimates at each data point. Variance of the noise in 
F . 5 . d 2- ( 2 * 2)/ h 2- 2 tgure IS COmpute as O"noise - O'comb - p O'comb p, W ere Ocomb - O'non-diseased 
+ 0diseasel To investigate the effect of differential noise, which, for example, is 
seen with blood pressure measurements, 50 the simulations were run again (Figure 
6) using different quantities of noise for measurements drawn from the non-
diseased and diseased distributions. Since variance is additive, the noise variance 
derived above was divided among the two populations proportional to their 
means: Onoise; non-diseasel = )lnon-diseased * <inoise 2/( Jlnon-diseased + J...ldiseased) and <>noise; 
disease/ = J.ldiseased * 0noise 
2
/( !lnon-diseased + ).!diseased). From these figures, one sees that 
prevalence has no effect on test characteristics even in the prevalence of noise. In 
the simulation involving differential noise, we note that sensitivity is degraded 
more by decreasing reliability than specificity as it was affected by a greater 
amount of noise. Again, there is no dependence on prevalence. 
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Figure 5: Sensitivity versus prevalence for varying levels of reliability. Noise 
was applied equally to measurements from diseased and non-diseased individuals. 
Note that both sensitivity and specificity are degraded equally and without 
dependence on prevalence. 
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Figure 6: Sensitivity versus prevalence for varying levels of reliability, but with 
differential noise. In this model of differential noise, measurements from 
diseased individuals experienced greater amounts of noise with a resulting more 
rapid decline in sensitivity as reliability declined. No dependence on prevalence 
is observed. 
21i 
ll.3.3 Single-Distribution Paradigm 
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Figure 7: Single-Distribution Model. A diagnostic threshold is used to subdivide 
a single distribution into diseased and non-diseased individuals. Since this 
distribution represents the known population of interest, selection of the threshold 
also determines the prevalence of disease. 
Decisions are frequently rriade in clinical medicine based on continuous 
distributions where the "diseased" distribution is unknown. Serum cholesterol 
and systolic blood pressure, for example, represent measurements that have 
defined diagnostic cut-offs that divide patients into two groups. Yet, these cut-
offs are not easily determined by a comparison of the distributions of these 
measures between diseased and non-diseased individuals. These cut-offs are 
typically determined by consensus expert opinion in relation to the distribution of 
values in the "normal" population. The difficulty arises because the underlying 
diseases which these measures may reflect are continuums in and of themselves. 
Diagnostic decisions are also frequently made on whether a laboratory value falls 
inside or outside the normal range, such as serum creatinine or white count. 
Since these diagnostic decisions are all based on a single distribution, I call this 
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the "single-distribution paradigm." This is also the paradigm that Brenner and 
Gefeller used for their investigations. 
Conceptually, a more useful view of the single-distribution paradigm may 
be to think of the decision threshold as dividing individuals into "low-risk" and 
"high-risk" groups for an underlying disease, such as coronary artery disease, 
rather than "non-diseased" and "diseased." The motivation for this view is that 
although we know the distribution of values in the population as a whole, 
individuals with higher values are more likely to develop disease than those with 
lower values. We also know that low values do not mean the individual is 
without risk. 
Figure 7 illustrates the single-distribution paradigm. The known 
distribution, which is typically that of healthy individuals, is subdivided into 
"diseased" and "non-diseased" on the basis of a decision threshold. Unlike the 
classic paradigm, the threshold is both an integral part of the definition of 
"disease" and determines the prevalence of"disease" in the population in this 
paradigm. The two distributions are also no longer independent. In the absence 
of noise and assuming no intra-subject variability, sensitivity and specificity are 
both 100%. 
Since the distribution of"diseased," or "high-risk," individuals and the 
distribution of"non-diseased," or "low-risk," individuals are dependent on each 
other, the addition of measurement uncertainty will affect test characteristics 
based on the position of the threshold. Since the threshold also determines the 
prevalence of disease, test characteristics will vary by prevalence in the presence 
2R 
of noise. Figure 8 illustrates the affect of measurement noise on test 
characteristics as a function of prevalence. This figure illustrates that even a 
modest amount of noise can not only dramatically degrade the value of the test, it 
does so extremely strongly as a function of prevalence. Since the reliability of the 
measurement can be degraded by making measurements from an individual from 
a subgroup with a different distribution, modest subgroup variation can still result 
in significant degradation of test characteristics. For example, measurements of 
liver enzymes are affected by BMI, age, and gender 5 1 Brenner and Gefeller also 
show similar patterns for positive and negative predictive values and likelihood 
ratios. 
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Figure 8: Variation of test characteristics in the single-distribution model versus 
prevalence by varying levels of measurement reliability. There is a significant 
dependence of the test characteristics on "disease" prevalence in the presence of 
reduced measurement reliability. 1bis simulation was based on a normal 
distribution with variance 4. Variance of the noise was computed as O"noU<e2 = 
( O"di,tribution2 - p*O"di,tribution2)/ p. Two hundred thousand samples contributed to each 
data point. 
II.3.4 Discussion 
Two paradigms exist in diagnostic testing. In the classic "two-distribution 
paradigm," the characteristics of diseased and non-diseased individuals are 
known. Based on this knowledge, optimal decision thresholds can be set after 
taking into account the relative costs of false positives and false negatives. 
Inherent in the "two-distribution paradigm" is the idea of separability. In general, 
the farther apart the two distributions are the better the performance of the test. 
The task in designing diagnostic instruments is to find the measure or set of 
measures that allows the greatest separaticm between the "diseased" and "non-
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diseased" distributions. A significant amount of attention has been devoted to this 
paradigm, both in the design and analysis of such diagnostic systems. The ROC 
curve, for example, is a construct that allows rapid assessment of the separability 
of two distributions. 
By contrast, the "single-distribution paradigm" makes use of a kuown 
distribution and makes diagnostic decisions regarding individuals at the tails of 
the distribution. Very little is kuown about the diagnostic characteristics of this 
system, yet this paradigm is used on a daily basis in every medical practice. 
Adverse event monitoring in clinical trials uses this paradigm as well. For 
example, studies of tacrine for Alzheimer 's disease monitor alanine 
aminotransferase levels in relation to multiples of the upper limits ofnormal52 
Brenner and Gefeller have made a major contribution by highlighting the 
problems with this system. As the simulations in the previous section show, even 
small decreases in measurement reliability can have dramatic effects on test 
characteristics. Since this paradigm is used on a daily basis, the implications for 
health care resource use can be enormous. Simply by conceptualizing individuals 
as "low-risk" or "high-risk" (for coronary artery disease, for example), there are 
major implications in terms of resource use. 
Perhaps the greatest flaw with the "single-distribution paradigm" is that 
there is no way of telling how useful a particular measure is for diagnosing 
individuals or for quantifying error rates. Since there is no second distribution 
with which to compare normal and diseased individuals, measures of separability 
do not exist. Thus, there is no way of comparing tests to each other. 
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Furthermore, withoutthe second distribution, one cannot calculate sensitivity and 
specificity for a test and know how it relates to the disease of interest. Simply, the 
truth about disease state is unknown and, therefore, no inferences based on 
disease state can be made. 
From the standpoint of subgroup variation, measurement noise does not 
create spurious prevalence-dependent subgroup variation when present in the 
classic "two-distribution paradigm" and it does in the "single-distribution 
paradigm." However; if measurements from the two subgroups in the classic 
paradigm are subject to different reliabilities, then one can have prevalence-
independent subgroup variation. Diabetics, for example, have lower variability in 
cholesterol measurements than non-diabetics. 53 
III Current Approaches 
A significant amount ofliterature has been devoted to the problem of 
imperfect reference standards and, increasingly, to analysis of subgroup variation. 
Methods for addressing the imperfect reference range from correction and 
estimation procedures to methods for augmenting less than perfect references in 
the hope of improving their accuracy. Since the focus of this paper is on 
subgroup variation, the focus here will be on methods that use subgroup variation 
to arrive at estimates of both the reference and the new test's characteristics. 
Emerging methods for handling covariates affecting test characteristics are 
extensions of regression models. A very brief overview will be provided here of 
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these methods. In addition, an interesting paper addressing subgroup variation in 
clinical decision making will also be discussed. 
III.l Imperfect Reference Standards 
As illustrated earlier, the imperfect reference is a common problem. Even 
if a perfect reference exists, it may be too expensive or invasive to be used on a 
scale that would provide accurate estimates of a new test's characteristics. Since 
new tests continue to be developed, and these tests need to be evaluated, methods 
for addressing this problem are required. Approaches for handling this problem 
have proceeded on two fronts: estimation procedures and augmentation methods 
for improving the accuracy of available reference tests. A brief description of 
estimation approaches and augmentation procedures will be given. This will be 
followed by a consideration of the usefulness of subgroups in test parameter 
estimation. 
Ill.l.l Estimation Procedures 
Estimation methods range from very simple algebraic methods to very 
complex iterative methods. Gart and Buck in 19663 and Staquet, et al.,4 in 1981 
described simple algebraic procedures for correcting reference test bias. Hui and 
Walter54 published a procedure based on maximum likelihood estimation in 1980, 
which served as a starting point for many of the more statistically rigorous 
procedures that followed. The development of these more sophisticated 
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techniques is driven by the need to account for conditional dependence between 
tests. See En0e, eta!., for a review of these methods55 
Conditional independence, the property of two tests where the probability 
of one test's result for a given disease state is not related the probability of the 
other test's result for the same state, is difficult to satisfy in reality. If both tests 
rely on blood sampling, then sampling error would affect both tests. If an 
imaging test is used as a reference for another imaging test, then anatomical 
features influencing diagnosis are likely to be present in both. Independence of 
tests is more likely when the physical basis of the tests is very different. An 
example would be the diagnosis of cancer by immunofluorescence of a tumor 
specimen and the detection of a mass on cross-sectional imaging. 
Early methods, such as those by Staquet, eta!., and Hui and Walter 
assumed conditional independence. Unfortunately, significant biases can be 
introduced when methods depending on conditional independence are used to 
evaluate conditionally dependent tests. See Torrance-Rynard and Walter for an 
analysis of this effect56 As a result, these simpler methods are not widely 
applicable. 
Latent class methods represent a special case. In this approach, there is no 
reference test and true disease state is considered latent, or unobservable. The 
results from multiple tests are used together to arrive at an estimate of the true 
state via iterative maximum likelihood estimation procedures. In the case of 
conditional independence, a minimum of three tests is required. Methods that 
account for conditional dependence require a minimum of four or more 
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simultaneously applied tests. 57 Like other approaches, using a three-test method 
that is intended for use when the tests are conditionally independent when the 
tests are actually conditionally dependent will result in biased estimates. 58 Albert 
and Dodd demonstrated that incorrectly specifYing the nature of the dependence 
also results in biases. 57 
Finally, Bayesian approaches exist for the estimation of test parameters as 
well. These require selection of prior probability distributions that model already 
known characteristics of tests. An overview is also given in Enoe, eta!. 55 
ill.1.2 Augmentation Methods 
Augmentation methods typically make use of a series of additional tests to 
improve the accuracy of the imperfect reference. Two methods will be mentioned 
here: discrepant analysis and composite references. Since these methods rely on 
imperfect reference tests, observed test characteristics vary with prevalence. 
Their use, therefore, does not eliminate the possibility of spurious subgroup 
variation. Discrepant analysis was used frequently in the evaluation of 
microbiological tests, but its use has since declined with recognition that this 
method has inherent limitations. Composite references seek to address the 
problems with discrepant analysis in a more bias neutral way. 
Discrepant analysis is a method for improving the estimates of a new 
test's characteristics via the resolution of discrepancies58·59•60 Discrepant analysis 
is a two-stage process, which is illustrated in Figure 9. In stage one, both the new 
test and the reference test are applied to each subject. The number of subjects 
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corresponding to each combination of test results is denoted nij, where i and j refer 
to the test result (+ or-) for the new and reference tests, respectively. In the 
second stage, individuals with discrepant results, represented by the n+. and n.+ 
cells, are tested again with the resolver test. The results of the resolver test trump 
the result of the reference in the first stage. Therefore, a proportion of subjects 
classified as false negatives in the first stage are reclassified as true negatives. 
Likewise, a proportion of subjects classified as false positives are reclassified as 
true positives. The effect of these two reclassifications is that the sensitivity and 
specificity observed for the new test in the first stage is improved in the second 
stage. This process is inherently biased. 
Figure 9: The Two Stages of Discreoant Analysis. 
Stage 1 Reference Test+ Reference Test -
New Test+ n++ n+-
New Test- n.+ !L 
N 
Stage 2 Resolver Test+ Resolver Test-
New Test+ ll+++ ll+-+ ll+--
New Test- ll.++ lL + ll.+-
N 
The number of subJects occumng wtth each combmatwn of test 1s giVen by nijk, 
where i, j, and k represent the test results ( + or-) for the new, reference, and 
resolver tests, respectively. A third subscript is present only when the resolver is 
invoked. In the second stage, discrepant results are resolved by the resolver test. 
The resolver trumps the reference for purposes of assigning subjects with 
discrepant results to a cell in the second stage. 
Hadgu,61 Miller,60 and Lipman and Astles62 have described the bias 
inherent in discrepant analysis when the resolver is 100% accurate. Since there is 
no process whereby a subject with concordant test results(++ or--) has an 
opportunity to be reclassified as a diagnostic error, i.e. a false positive or false 
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negative, discrepant analysis falsely improves the new test's sensitivity and 
specificity. Since an imperfect reference is involved, the magnitude of the bias is 
dependent on prevalence.60 Thus, spurious subgroup variation is possible when 
using discrepant analysis in subgroups with differing prevalences. When the 
resolver is not 100% accurate biases may be larger in magnitude, but may be in 
either direction. 63 When the new test and resolver test are not conditionally 
independent, biases can also be significantly larger. 60 
Composite reference tests address the shortcomings in discrepant analysis 
in two ways. First, the reference test is a combination of tests that are chosen for 
their complementary characteristics. Several highly specific tests with less than 
perfect sensitivities but with differing underlying technologies, such as culture 
and polymerase chain reaction (PCR), are combined such that the sensitivity of 
the composite is greater than for each test alone. Second, unlike discrepant 
analysis, evaluation ofthe "true" state of a subject is independent of the new test. 
All subjects have the opportunity to be evaluated by all tests in the reference 
independent of the result of the new test. 
The execution of the composite reference can be done sequentially or all at 
once. In sequential testing, tests are performed in a set order. The idea is to select 
the initial tests to have perfect specificity. These tests are performed until one of 
the tests is positive. Since a perfectly specific test does not make false positive 
errors, the sequence can be stopped64 Alternatively, perfectly sensitive tests 
could be chosen and the sequence executed until a negative test result is achieved. 
Alonzo and Pepe have described a sequentially applied reference, culture then 
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PCR, for the evaluation of an enzyme immunoassay (EIA) for Chlamydia 
trachomatis58 Sequential testing also has the potential to save resources by 
limiting the total number of actual tests performed. 
Although sequential application of the reference tests is attractive, there is 
one potential problem. Delay in obtaining the additional tests in the sequence 
could result in interim changes in a subject's disease state. Thus, the new test and 
one or more of the initial reference tests are making measurements on one disease 
state while subsequent measures are measuring a different disease state. 
Implementation of sequential testing procedures should ensure that all tests be 
performed within a relatively small time window. 
The evaluation of tests intended for screening applications is a special case 
where a composite reference is required. For example, finding an abnormality on 
screening mammography initiates further testing, including additional imaging 
and potentially biopsy. For evaluation of negatives, it is not feasible or ethical to 
subject every woman with a negative mammogram to additional studies. Long-
term follow-up is, therefore, required to adjudicate the "true" state. Another 
example would be the comparison of thin-prep and liquid-based cytological 
methods for cervical cancer detection. Follow-up is the only way to ascertain true 
disease state in women with negative results. In this case, the reference chosen is 
dependent on the result of the test under study, but a test is applied in every case. 
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ll.1.3 Using Subgroup Variation For Test Characteristic Determination 
To this point, prevalence-dependent subgroup variation due to an 
imperfect reference has been presented as something to be avoided. Here, 
however, the use of this type of subgroup variation to determine the 
characteristics of the reference test is presented. Since imperfect reference tests 
are commonly employed, it would be helpful to know what the actual 
characteristics of the reference are in the populations being studied. Even 
augmented references should be evaluated in this retrospective fashion to have an 
idea of how much bias may be present in the data. 
The use of subgroup variation to help with estimation of test 
characteristics when the characteristics of the reference test are unknown was first 
developed by Hui and Walter in 198054 Under the assumption that variation is 
due only to differences in disease prevalence between the groups and that both the 
reference test and the new test have the same, albeit unknown, characteristics in 
both subgroups, they derived closed form expressions for estimates of both test's 
sensitivity and specificity and the actual disease prevalences in each group. As 
noted previously, a significant amount of work has been done to extend Hui and 
Walter's original work However, the active use of subgroups to quantify the 
effects of an imperfect reference is quite limited in the diagnostic test literature. 
Two examples are Shaw et al65 and Berger et al 66 in the human literature. See 
En0e et al55 for additional examples from the human and veterinary medicine 
literature. 
39 
In this section, Hui and Walter's closed-form estimation equations and an 
alternate derivation based on Staquet et a!.' s work resulting in a somewhat 
different set of equations will be presented. Simulations are presented to 
understand the behavior of these equations under a variety of situations. Figure 
10 shows the 2x2 contingency tables for the two subgroups and the notation used 
in the formulas. 
Figure 10· 2x2 Contingency Tables for 2 Subgroups with Different Prevalences 
Subgroup 1 Reference Test+ Reference Test-
New Test+ a1 bl 
New Test- C! dl 
e1 =a1+c1 fl = bl+dl 
Subgroup2 Reference Test+ Reference Test-
New Test+ a2 b2 
New Test- c2 d2 
ez- a2+c2 fz- b2+d2 
.. SensRef, SpecRer- SensitiVIty and specifiCity of the reference 
SensNew, SpeCNew- Sensitivity and specificity of the new test 
ID.1.3.1 The Equations of Hui and Walter 
gl = a1+b1 
h1 = C1+d1 
N1 
gz = a2+b2 
h2 = Cz+d2 
N2 
Starting with a multinomial model, Hui and Walter derived closed form 
expressions for the sensitivities and specificities of both the reference and new 
test and the disease prevalences in the two subgroups via the method of maximum 
likelihood estimation. Figure 11 illustrates this model. 
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Figure 11· Cell Probabilities Used in the Multinomial Model 
Reference Test+ Reference Test-
New Test 
+ Previ * SensNew * SensRef Previ*SensNew *(1-SensRef) 
+ (1-Prev;)*(1-SpecN,w)*(1-SpecR,r) + (1-Prev;)*(1-SpecN~,)*SpecR,f 
New Test 
-
Previ*(l-SensNew)* SensRef Prev; *(1-SensNew)*(l-SensRor) 
+ (1-Prev;)*SpecN,w *(1-SpecR,r) + (1-Prev;)*SpecN,w *SpecRef 
P I • . I n' "1 :_P-:.( R::eeflcce:c.s:....l+:.:_, N.,.:-ewc..T,:....e.:.:st_:_+ )'-"- ,P_,( R:c.ecc'fl:....e.:.:st-:-,.:.:N..:._ew:_::'J,.::.:es::_t+"')_• mu tmomra == 1v1. -
;,1 ad bd 
* P(Re/fesl+, NewTest-)"' P(Rejrest-,NewTest-l' 
cd dd 
Using the notation used by Enoe et al.,55 tbe equations they derived are: 
S (g,e,- e,gJINN, + aJN,- a/N, + F ensRq = , 
2(gJN,- g/NJ 
S (fih,-hfJINN,+d/N,-dJN,+F peCR<if = . , 
2(gJM- g/NJ 
Prev, = 0_5 _ [(g/NJ(e/N,- eJNJ + (e/NJ(g/N,- gJNJ + aJM- a/N,]' 
. 2F 
Prev, = 0_5 _ [(g,/N,)(e/N,-eJNJ+(e,/N,)(g/M- g/NJ+aJM-a/M]' 
2F 
Where, 
As noted by Hui and Walter, these equations provide two sets of solutions 
based on tbe sign ofF: the actual parameter and one minus the parameter. Since 
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it is unlikely that a worthwhile reference test will have a sensitivity or specificity 
less than 0.5, it should be easy to select the appropriate solution. Prior knowledge 
about the test should also be helpful in selecting the appropriate solution. Another 
difficulty is that division by zero is encountered in the test parameter formulas 
when the new test's parameters (SensNew and SpeCNew) are being calculated and 
the measured prevalences as determined by the reference test are equal between 
the two subgroups and vice versa. In situations were there is insufficient prior 
information to help select the appropriate solution or one is near a singularity, 
iterative methods will be required. 
III.1.3.2 Direct Algebraic Approach 
III.1.3.2.1Reference Test Characteristics Known 
Figure 12: 2x2 Contingency Matrix Showing Cell Count Corrections For 
Imperfect Gold Standard With Known Characteristics 
Reference Test+ Reference Test-
New Test+ (a- b*(l/SpecRe~·-1))/SensR,f (b- a*(l/SensRer- 1))/SpecRef 
New Test- (c- d*(l/SpecRer- 1))/SensRef (d- c*(1/SensR,r-1))/SpeCRef 
As preamble to the derivation for the case with unknown reference test 
characteristics, formulas for the estimates of the new test's characteristics when 
the reference test characteristics are known are given here. Both Staquet et a!. 4 
and Gart and Buck3 provide algebraic methods for correcting observed test results 
when the characteristics of the imperfect reference standard are known. Figure 12 
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shows the corrections for known reference test characteristics to the observed cell 
counts. Formulas for sensitivity, specificity, and prevalence follow from these 
corrections: 
S (a+b)*Spec&J-b enSNew = , 
N* SpeC&J-(b+d) 
S (c+d)*SenSReJ-C ~eCNew = , 
N* SenSReJ-(a +c) 
Prev= N*(SpecR<J-l)+(a+c). 
N * (SensRef + SpeC&f -1) 
With these equations, special cases can be considered. First, we note that 
the correction for sensitivity is dependent only on the specificity of the reference 
and the correction for specificity is dependent only on the sensitivity of the 
reference. Thus, in the event that the reference test is known to have 100% 
specificity, the observed sensitivity is no longer biased: 
a SensNew = ~-, SpeCReJ= 1.0 
a+c 
Similarly, if the reference test is known to have 100% sensitivity, then the 
observed specificity is no longer biased: 
d SpeCNew = --, SenSRej= 1.0 
b+d 
Ifboth tests have 100% specificity, then the sensitivities of the two tests are: 
a a SensNew = ~- andSens&J = ~-. 
a+c a+b 
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III.1.3.2.2Reference Test Characteristics Not Known 
The derivation for the case where the characteristics of the reference test 
are not known is based on the formulas developed above. Under the assumption 
that the reference test and new test have the same characteristics in both 
subgroups, the following equalities hold: 
(a,+ b,)SpecRef- b, (a,+ b,)SpeCRef -b, 
N.SpeCRef- (b, + d,) N,SpeCRef- (b, + d,)' 
(b, + d,)SensN,w- b, (b, + d,)SenSNew -b, 
N,SenSNew- (a,+ b,) N,SenSNew- (a,+ b,)' 
(a, + c, )SpeCNew- c, (a, + c, )SpeCNew- c, 
N,SpeCNew-(c, +d.) N,SpecN,w-(c, + d,) 
As the solutions to these equations are similar, only the derivation for the 
estimate of SensRef is presented here. Manipulation of the equation for SensRef 
results in the following quadratic equation 
Let 
Then 
[N ,(c.+ d,)- N,(c, + d,))sens Ref' 
+[(a,+ c.)( c.+ d,)- (a,+ c.)( c.+ d.)+ c,N,- c,N,)sensR,f 
+ [c,N,- c,N,]= 0 
C = [c,N,- c,N,]. 
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-(B/A)±~(BI A)2 -4(CI A) 
SensRef= . 
2 
Table 3 shows the analogous A, B, and C components of the quadratic 
fonnula for the other test characteristics. 
Table 3: Components of the Estimating Equation for The New and Reference 
Tests 
SensRef SpeCRef SensNew SpeCNew 
A N2(c,+d1)-N1 (c,+d2) = N2(a1+b1)-N1(a2+b2)- N,(b1+d1)-N1(b2+d2)- N2 (a1+c1)-NJ(a2+c,) = 
h1N2-h2N1 g1N2-g2N1 f1N2-f2N1 e1N,-e,N1 
B (a1+c1)(c,+d2)- (b1+d1)(a2+b2)- (a1+b1)(b2+d,)- (c1+d1)(a2+c,)-
( a,+c,)( c1+d ,)+c,N r (b2+d2)(a1+b1)+b2N1- ( a2+b2)(b1+d 1)+b2N 1- ( c,+d2)(a1+c1)+c,N1-
c1N2= b1N2 = b1N2 = c1N2= 
e1h,-e,h1+c,N1-c1N2 f 1g,-f,g,+b2N1-b,N, g1f,-g2f1+b2N1-b1N2 h1e,-h2e1+c,N1-c1N2 
c c1(a2+c,)-c,(a1+c1)- b,(b,+d,)-b,(b,+d,)- b1(a2+b2)-b2(a1+b1)- c1(c,+d2)-c,(c1+d1)-
c1e2-Y:e1 b,f,-b,f, b,g,-b,g, c1h,-c,h1 
• Parameter= 
- (BIA)+~(BI A)2 - 4(C I A) (Direct Equation) 
2 
. -(BIA)-~(BI A)' -4(C I A) . . 
• (1- ParameterCompamon)= (Induect Equatwn), 
2 
• Where, for a given test, the companion parameters are sensitivi1y and specifici1y. 
• For the Hui and Walter equations, the +F solution will be referred to as the "direct 
equation" and the -F solution will be referred to as the "indirect equation." 
Comparison between the equations ofHui and Walter and the equations 
developed here shows significant similari1y. Since each 2x2 contingency table 
has three degrees of freedom (knowledge of total N and the contents of three of 
the cells is sufficient to detennine the contents of the fourth cell), the contents of 
only three cells from each subgroup is required for estimation. The Hui and 
Walter equations and those developed here differ only in which three cells are 
used. 
The algebraically derived equations and those of Hui and Walter are 
compared through simulations in Figures 13 through 16. In each figure, one of 
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the four test parameters is varied while the other three are held constant. Plotted 
in each graph is the direct solution (see Table 3 for definition) and the 
complementary solution. There are several points to be noticed from inspection 
of these plots. The first is that the results provided by both methods are identical 
(with one exception discussed below). The second is that the direct root is not the 
complement of the indirect root. Rather, the indirect root is the complement of 
the test's companion parameter. For example, if calculating SensRef, then the 
indirect root is (1-SpecRef). Thus, the solution for all four test parameters can be 
obtained via two general equations. 
The point where division by zero occurs in the evaluation of the equations 
manifests in a different fashion depending on which parameter is being varied. 
The points were discontinuities exist are given by the general relation: estimated 
test parameter= 1 -estimated companion parameter. For example, when SensRef 
= 1 - SpecRef· Thus, there are four potential discontinuities: SensRef = 1 - SpeCRef, 
SpeCRef = 1 - SenSRef, SenSNew = 1 - SpeCNew, and SpeCNew = 1 - SensNew· When 
one of these conditions applies for the reference test, there is a resulting division 
by zero when estimating the parameters of the new test. Significant instability in 
these estimates occurs as the reference test parameters approach the discontinuity. 
The analogous situation occurs when one of the discontinuity relations is satisfied 
by the new test. 
Curiously, the roots of the estimating equations flip roles at the 
discontinuities. For example, when estimating SensRef, but SensRef < 1 - SpeCRef, 
the direct root now provides an estimate of I - SpeCRer and the indirect root 
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estimates SensRef· For the Hui and Walter equations, the flipping of roles occurs 
for all parameter estimates. For the newly derived equation, this does not happen 
when estimating the parameters of the new test. Although the likelihood that any 
of the discontinuity conditions is satisfied for the reference test is rare, this may 
occur for a new test. Since one does not generally know a priori how the new test 
will fare, using the new equations for estimating the new test's parameters at least 
ensures that the direct equation is always providing an estimate of the parameter 
of interest. 
What is the minimum difference in disease prevalence between the two 
subgroups that will provide reasonable estimates of the test parameters? This 
question is qualitatively explored in Figure 17. The prevalence of disease in 
subgroup 1 was held constant at 0.10 and the prevalence was incrementally 
increased in subgroup 2. The variability in the resulting estimates decreases 
significantly when the difference in prevalence is 0.10. Some additional gains are 
achieved when the difference is 0.20. 
ID.1.3.2.3Summary 
In this section, Staquet et a!.' s equations for correcting the observed 
characteristics of a new test given the known characteristics of an imperfect 
reference test were extended to provide estimates for the unknown parameters of a 
reference test with the addition of information from a second subgroup. The 
resulting equations are equivalent to Hui and Walter's equations, which were 
based on maximum likelihood estimation. One significant difference is noted, 
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however. The new direct estimating equations for the characteristics of the new 
test always provide an estimate of the parameter of interest. The direct Hui and 
Walter equations, however, flip roles when SensNew < 1- SpeCNew (and vice 
versa). When this situation exists, then the estimate of the parameter of interest is 
provided by the indirect equation (corresponding to the negative F term). Since 
there is much greater potential variability in the resulting parameters of the new 
test than in the reference test, which presumably was chosen because it is a good 
test, the probability of a role reversal is greater when estimating the characteristics 
of a new test. When it is reasonable to assume conditional independence and that 
the tests perform similarly in both subgroups, the new equations are preferable. 
These equations are dependent on a difference in disease prevalence to 
work. Otherwise, the two subgroups could be combined into a single group. The 
qualitative effect of changing the magnitude of the differences in prevalence on 
variability in the resulting parameter estimates was explored. Based on these 
simulations, an absolute difference of 10% provides relatively stable estimates. 
No further improvements were noted after an absolute difference of20%. 
Increasing the sample size will also improve the stability of the estimates. If one 
parameter is more important than the other, then appropriate prevalences can be 
chosen. For example, if a more accurate estimate of sensitivity is desired, the 
prevalences in both subgroups should be high as there is more data on which to 
base this estimate. 
These equations cannot be used in the presence of true subgroup variation. 
In this case, eight parameters (sensitivity and specificity of the new test in both 
4S 
subgroups and for the common reference test plus the prevalences of disease in 
the two subgroups) have to be estimated. Only six degrees of freedom are 
available with two subgroups, so at least one additional subgroup would be 
needed. Only iterative methods exist to handle this situation. If the magnitude of 
the subgroup variation for the new test is known, then the new equations can be 
extended to take the difference into account. 
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Figure 13: Estimation of Test Parameters- Actual SensRef Varied. Actual 
SpecRer= 0.95, SenSNew = 0.75, and SpeCNew = 0.95. SenSRervaried from 0.02 to 
1.0 in 50 increments. The prevalence of subgroup I = 0.10. The prevalence of 
subgroup 2 = 0.40. 30,000 subjects were used in each group. Solid lines are 
estimates from the direct equations. Dotted lines are estimates from the indirect 
equations. (H& W = Hui and Walter equations.) 
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Figure 14: Estimation of Test Parameters- Actual SpecRef Varied. Actual SensRef 
= 0.80, SenSNew = 0.75, and SpeCNew = 0.95. SpeCRervaried from 0.02 to 1.0 in 50 
increments. The prevalence of subgroup 1 = 0.10. The prevalence of subgroup 2 
= 0.40. 30,000 subjects were used in each group. Solid lines are estimates from 
the direct equations. Dotted lines are estimates from the indirect equations. 
(H& W = Hui and Walter equations.) 
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Figure 15: Estimation of Test Parameters- Actual SensNew Varied. Actual 
SenSRef= 0.80, SpeCRer= 0.95, and SpeCNew= 0.75. SenSNew varied from 0.02 to 
1.0 in 50 increments. The prevalence of subgroup 1 = 0.10. The prevalence of 
subgroup 2 = 0.40. 30,000 subjects were used in each group. Solid lines are 
estimates from the direct equations. Dotted lines are estimates from the indirect 
equations. (H&W = Hui and Walter equations.) 
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Figure 16: Estimation of Test Parameters- Actual SpecNew Varied. Actual 
SensRer= 0.80, SpecRer= 0.95, and SensNew = 0.75. SpeCNew varied from 0.02 to 
1.0 in 50 increments. The prevalence of subgroup 1 = 0.10. The prevalence of 
subgroup 2 = 0.40. 30,000 subjects were used in each group. Solid lines are 
estimates from the direct equations. Dotted lines are estimates from the indirect 
equations. (H&W = Hui and Walter equations.) 
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Figure 17: Effect of Prevalence Difference on Parameter Estimation. (Figure 
continued on next page.) Prevalence of subgroup 1 = 0.10. Prevalence of 
subgroup 2 = 0.10 + the prevalence difference. Sp~.r varied from 0. 02 to 1. 0 in 
50 increments. 30,000 subjects were used in each group. Solid lines are 
estimates from the direct equations. Dotted lines are estimates from the indirect 
equations. As the prevalence difference increases, the estimates of SenSNew 
experience less variability. The other parameters behave similarly. Since lower 
prevalences were chosen, estimates of sensitivity provide a worse-case scenario. 
(H&W = Hui and Walter equations.) 
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Figure 17: Effect ofPrevalence Difference on Parameter Estimation (continued). 
ill.2 Subgroup Variation 
Methods for handling subgroup variation in diagnostic tests are similar to 
those for handling subgroup variation in other areas of clinical medicine and vary 
from the simple to the complex. The simplest method is to simply acknowledge 
its existence. The most complex methods make use of regression techniques to 
model the effect of co variates on a test's sensitivity and specificity. Once 
subgroup variation is identified, bringing that knowledge into clinical practice is 
the final step. 
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Statistical techniques will be overviewed in the first part of this section 
and papers by Goehring et al.67 and Schmitz eta!. 68 discussing approaches to 
handling "spectrum bias" in clinical decision making will be examined in the 
second part. 
Ill.2.1 Statistical Approaches 
Subgroup analysis is the most straightforward approach to assessing 
subgroup variation in diagnostic tests. As noted by Mulherin and Miller, 
subgroup variation is an example of effect modification. 5 Since the test performs 
differently in different subgroups, heterogeneity should be tested for after 
stratification on specific subgroups and, when found, analysis should stop. The 
subgroup-specific test characteristics should be reported as separate entities. The 
caveat to such analysis is that there need to be sufficient samples in each subgroup 
to allow reasonably accurate estimates of the subgroup-specific parameters. The 
corollary of this caveat is that it is incorrect to assume that it is okay to report an 
aggregate result when the sample size is too small. The results from a study with 
too small a sample size, regardless of whether it is a diagnostic study or an 
intervention study, are not likely to be valid. Simel et al69 and others70•71 have 
published guidelines for properly powering diagnostic test studies. See also the 
text by Pepe for a full discussion of sample size issues. 72 These principles now 
need to be extended to subgroup analysis. 
Regression techniques allow for the simultaneous consideration of 
multiple covariates at one time. There are three advantages to this approach. 
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First, fewer samples are required than for an analogous analysis based only on 
stratification. Second, continuous variables, such as age, can be incorporated 
without difficulty. Finally, prediction models are generated by such methods that 
have the potential to be used by clinicians. 73 
Regression approaches for diagnostic tests first appeared in the early 
1990s. In 1992, Coughlin eta!. proposed a technique for modeling sensitivity, 
specificity, and the predictive values directly with a regression model74 Since 
that time, the focus in regression modeling has been on the likelihood ratio (LR). 
Knottnerus,75 Simel et al.,76 and Leisenring and Pepe77 have proposed models, 
with varying pros and cons, that predict positive and negative LRs. The latest 
installment in regression paradigms for diagnostic tests is that proposed by 
Janssens et a!. in 2005. In this model, the ability to account for previous tests is 
also included. As a result, their model allows for the prediction of the incremental 
value of each additional test. 
The fact that subgroup analysis is not performed cannot be blamed on the 
lack of statistical techniques. Although these techniques have lagged behind their 
brothers in the intervention study literature in the amount of attention they 
receive, there do exist viable and sound techniques for addressing the problem of 
co variates. 
ill.2.2 Spectrum Bias and the Likelihood Ratio 
Goehring et al67 suggest that spectrum effect, as defined by Mulherin and 
Miller,5 is more common than spectrum bias in the actual study and use of 
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diagnostic tests. In their definition of spectrum bias, they refer to a difference 
between the aggregated likelihood ratios and that of a specific subgroup. To 
support this claim, they develop a new test statistic, called spectrum bias, and 
apply it to a few examples in the literature. 
The test statistic spectrum bias is simply the ratio of the subgroup-specific 
likelihood ratio divided by the aggregated likelihood ratio: 
. LRrub 
spectrum bzas= , 
LRaggregate 
where LR can refer to either the positive ( +) or negative (-) LR, which are given 
by: 
LR+ = sensitivity 
1- specificity 
LR- = 1- sensitivity . 
specificity 
If spectrum bias is close to unity, then there is no spectrum bias and 
clinical decision making is not affected by the subgroup variation. How might 
this be possible ifthe test characteristics differ? Ifthe sensitivity and specificity 
of a test vary in opposite directions between subgroups, one can still get identical 
LRs. For example, if sensitivity= 0. 75 and specificity= 0. 75 in one subgroup, 
the LR+ = 3.0 (0.75/0.25). If in another subgroup the sensitivity= 0.66 and the 
specificity= 0.78, the LR+ is also= 3.0 (0.66/0.22). Goehring et al. provide a 
formula for the confidence interval for this statistic. If the confidence interval 
includes 1.0, then there is no spectrum bias. 
'iS 
Three examples are cited, which include the urine dipstick for urinary tract 
infection study by Lachs et al.,9 the exercise stress test for coronary artery disease 
study by Moons et al., 11 and the exercise electrocardiography for left ventricular 
hypertrophy study by Levy et al. 17 These studies and subgroup-specific test 
parameters are listed in Table 1 and again in Table 4 below. Table 4 lists, in 
addition to the test characteristics, the sample size, LR+, LR+ ratio, and the 95% 
CI for the LR+ ratio. Inspection of the table shows that the likelihood ratios truly 
are different for different subgroups in the urine dipstick for urinary tract 
infection9 and electrocardiography for left ventricular hypertrophy studies. 17 In 
the exercise test for coronary artery disease study, the LRs for the aggregated 
sample versus the women-specific sample are not different based on the 
confidence interval for the LR+ ratio despite significantly different sensitivities. 
The confidence interval in this case is particularly wide, so sample size may be an 
issue. However, this and other subgroups (not shown) from the Moons et al. 11 
study all have varying sensitivities and specificities, but have LR + s in the vicinity 
ofl.O 
Table 4: The LR+Ratio and Spectrum Bias. Bolded ratios indicate characteristics 
significantly different from unity 
Study Subgroups N Sens Spec LR+ LR+ 95%CI 
Ratio 
Lachs' Aggregate 362 83.1 71.8 2.86 1.00 
High-Risk 102 92.5 42.9 1.59 0.6 0.4-0.07 
Moons" Aggregate 295 57.5 92.0 7.25 1.00 
Women 73 29.7 97.2 10.0 1.4 0.2-8.8 
Levy11 Aggregate 4684 7.2 98.9 6.55 1.00 
Bottom 2 quartiles BMI 1320 10.1 99.6 25.3 2.7 1.04-6.1 
Top 2 quartiles BMI 1320 5.0 99.1 5.56 0.6 0.4-0.97 
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The assertion that LRs for subgroups do not change much because 
subgroup test characteristics tend to vary in opposite directions does not hold for 
large groups of tests. Microbiological tests frequently have specificities of 100%. 
The only variation is in sensitivity. Examination of Tables I and 2 also provide 
additional examples were this assertion is not true. It is incorrect to conclude 
from their assertion that spectrum bias is not often present. 
Schmitz et al. suggest the use of stratum-specific likelihood ratios in 
mental health screening as "they are less subject to spectrum bias."68 (p. 376) When 
considering a test based on a continuous or ordinal scale, such as a variety of 
mental health screening instruments, a single diagnostic threshold determines 
"case" from "non-case." As discussed previously, values in the vicinity of the 
threshold give rise to greater uncertainty in diagnosis than values at the extremes 
do. To capture this effect, the range of possible values is subdivided into multiple 
regions: likelihood ratios for regions at the extremes reflect greater diagnostic 
certainty and those near the middle reflect less diagnostic certainty. Schmitz eta!. 
refer to these regions as strata- hence, the term "stratum-specific likelihood 
ratios." Their use is different from considering subgroup variation after 
stratification on a particular variable, which leads to a different kind of stratum. 
The stratum-specific likelihood ratios of Schmitz et a!. do not directly 
reflect subgroup-specific test characteristics. They directly reflect the use of 
multiple thresholds for the same test, which are good for capturing varying 
severities of disease. For the typical test, a single threshold is chosen to optimize 
the performance characteristics in the population of study. Thus, when a test is 
no 
developed in a wide variety of disease severities, but is then used only as a 
screening tool, the single threshold may be too high. Multiple thresholds capture 
more information. When thinking of "spectrum" as disease severity, spectrum 
bias can be mitigated by the use of stratum-specific likelihood ratios. When 
viewing "spectrum" in reference to other subgroups such as age, sex, or immune 
status, stratum-specific likelihood ratios are not helpful. 
The work presented by Goehring et al. and Schmitz et al. reminds us that 
tests are used to inform clinical decisions. Whether a patient belongs to a 
subgroup is an important consideration. It may be that membership in a particular 
subgroup does not radically alter the use of a test, but, on the other hand, it can 
have a profound difference. The spectrum bias statistic is a potentially helpful 
tool in evaluating this relationship. When a test is likely to be used in populations 
with differing disease severities, continuous or ordinal-valued tests provide the 
capability for multiple thresholds that allow for stratum-specific likelihood ratios. 
Although not the ideal solution, stratum-specific likelihood ratios provide more 
information about patients over the range of test values likely to be observed. 
IV Distinguishing True Subgroup Variation From The 
Effect of an Imperfect Reference 
The preceding discussion investigated sources of subgroup variation, 
which included spurious variation due to an imperfect reference test in subgroups 
with different disease prevalences, and an overview of methods for addressing 
imperfect reference standards. In this section, a methodology for distinguishing 
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true subgroup variation from the effect of an imperfect reference will be 
presented. 
The approach depends on whether the characteristics of the reference test 
are known. If the characteristics of the reference test are known, then the 
corrected sensitivity and specificity can be calculated for each subgroup via 
Staquet et a!.' s equations. If subgroup variation persists, then the variation is 
most likely real. If the variation vanishes, then the variation was due to the 
imperfect reference. 
When the characteristics of the reference test are not known, the process is 
more complex. First, the apparent prevalence of disease in the two subgroups 
should be evaluated. If they are similar, then the variation is likely real. If they 
are dissimilar, however, a second pair of subgroups is needed. There are two 
properties of the second pair that would be helpful. First, if the disease 
prevalence is different in both subgroups, but the observed test characteristics are 
the same, then the reference test is perfect (or near perfect). In this case, the 
variation in the first subgroup is most likely real. Second, if the likelihood of true 
subgroup variation in the second subgroup is very low (based on biological 
plausibility or past experience), but the groups have different apparent disease 
prevalences, the characteristics of the reference test can be estimated using the 
Hui and Walter equations, the equations developed here, or a more advanced 
method. These characteristics can now be applied to the original subgroup pair. 
If the variation is eliminated, then it was more likely due to the imperfect 
reference. Otherwise, the variation is more likely to be real. Reasonable 
o2 
candidates for the second subgroup, depending on the test, would be study site, 
age group, or gender. 
There are two caveats to this methodology. The first is that conditional 
dependence between the tests requires the use of advanced estimation procedures. 
The second is that the reference test can also exhibit subgroup variation. In this 
case, advanced estimation procedures are required involving multiple subgroups. 
Thus, the approach presented here requires conditional independence between 
tests and that the reference standard exhibits no subgroup variation among the 
subgroups being tested. 
V Summary 
In this paper, three potential sources of subgroup variation were examined 
with a focus on true subgroup variation and spurious variation due to an imperfect 
reference standard. The high prevalence of both true subgroup variation and the 
use of imperfect reference standards were emphasized. In particular, true 
subgroup variation represents effect modification and should be reported separate 
from aggregated results. For completeness, measurement noise, as a third 
potential source of subgroup variation was also discussed. 
Current approaches for managing imperfect reference standards and for 
identifying subgroup variation were discussed. A considerable amount of 
discussion was devoted to the analysis of imperfect reference standards as these 
are commonly employed and there is a large body of literature devoted to 
estimation in the presence of an imperfect reference and for constructing more 
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robust reference tests. Particular emphasis was placed on the Hui and Walter 
equations and an alternate set derived here from the equations of Staquet et a!. for 
two reasons. First, they use subgroups to identifY useful information, namely the 
properties of the reference test. Second, these equations are accessible to the non-
biostatistician. Beyond these equations, significant statistical knowledge is 
required, whereas the derivation of the new set of equations requires only algebra. 
Methods for identifYing clinically relevant covariates in diagnostic test 
performance are not much different from performing subgroup analysis in any 
other study. Identifying relevant subgroups and testing for heterogeneity are the 
basis for the simplest analyses. Logistic regression models have been extended to 
address the specifics of diagnostic testing. A model was also presented for 
considering the impact of subgroup variation on clinical decision making. 
Finally, a methodology for distinguishing true subgroup variation from 
spurious subgroup variation due to an imperfect reference standard was presented. 
The basis depends on differing prevalences between subgroups. If the 
prevalences of disease are the same, then an imperfect reference cannot cause 
spurious subgroup variation. If the prevalences are different, then the approach 
centers on identifYing the unknown properties of the reference on a second pair of 
subgroups and applying it back to the original subgroup. The Hui and Walter 
equations and the similar equations developed here are central to this approach. 
The discussion of Brenner and Gefeller's paper brought up two paradigms 
for thinking about diagnostic testing in relation to continuous measures. The 
"two-distribution paradigm" is the typical paradigm for thinking about diagnostic 
tests: there are separate distributions for both diseased and non-diseased 
individuals. The concept of separability is central to the analysis and design of 
tests in this paradigm. The "single-distribution paradigm" is not the usual model 
for thinking about diagnostic tests. In this model there is only a single 
distribution, but a threshold divides the distribution into "normal" and "not 
normal." The location of the threshold has implications for both the nature of the 
"normal" and "not normal" distributions and the prevalence of disease. Equally 
unreliable measurements in the "two-distribution paradigm" degrade performance 
but do not do so in a prevalence-dependent fashion. In the "single-distribution 
paradigm" the noise will affect the "normal" and "not normal" distributions 
differently depending on the location of the threshold. Thus, measurement noise 
causes prevalence-dependent changes in test characteristics in this paradigm. 
Studying diagnostic tests can rapidly become very difficult. Accounting 
for imperfect reference standards alone frequently requires far more than simple 
algebraic corrections. Although managing subgroup variation in studies of 
diagnostic tests is not significantly more difficult than managing subgroup 
variation in intervention studies, the interaction with an imperfect reference can 
cause the difficulty level to increase dramatically. Two methods for improving 
the quality of diagnostic test studies are to include a biostatistician skilled in the 
estimation procedures described above in both the design and analysis phases and 
to follow standard reporting guidelines. 
The Standards for Reporting of Diagnostic Accuracy (ST ARD) Initiative 
produced a 25-item checklist designed to improve the quality ofreporting of 
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diagnostic test studies. 41 There are five items (item #7 to #11) addressing the 
qualities of the reference standard and a single item (item #23) related to 
subgroups. The items related to the reference standard require justification for 
choice of the reference and technical specifications for the proper execution of the 
reference. For the cases were a human observer is an integral component of the 
test, the training and masking of the observer should be reported as should the 
availability of additional clinical information. The item addressing subgroup 
analysis states that "estimates of variability of diagnostic accuracy between 
subgroups of participants, readers or centers, if done"Error! Bookmark not dermed. (p. 42l 
should be reported. 
Based on the preceding discussion, some recommendations for clarifying 
and enhancing the STARD checklist follow. First, given that imperfect reference 
standards are common, the characteristics of the reference test should be reported 
along with the justification for its use. If an augmented reference is used, the 
performance of all tests together should be reported. Second, the discussion 
should comment on the effect the imperfect reference had on the observed test 
results. Third, studies should consider potential subgroup variation in the design 
phase and plan for an appropriate sample size. Alternatively, the evaluation 
should be limited to a very specific population. Fourth, if subgroup variation 
exists, sources of artifact should be sought and reported. Finally, clinically 
relevant subgroups should be analyzed and reported separate from aggregated test 
characteristics. 
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